Better testing for central nervous system cancers
Belay offers three proprietary CSF liquid biopsy tests, each clinically validated to help inform the diagnosis and management of primary and secondary brain and spinal cord tumors.
Using licensed technology based on extensive scientific research conducted at Johns Hopkins University for over 10 years, Belay has developed a proprietary molecular testing platform.
- Unlike currently available alternatives like cytology, MRI scans, or brain biopsies, our proprietary testing offers a highly accurate, minimally invasive and comprehensive molecular profile.
- CSF cytology has low sensitivity and excludes genomic data. Imaging lacks specificity and molecular insights. Brain biopsies are challenged with insufficient tissue volume, tumor heterogeneity, and patient morbidity and mortality risk.
Our CSF Liquid Biopsy Tests
Belay Summit™ 2.0
Comprehensive genomic profiling of tumor-derived nucleic acid in CSF to help inform the diagnosis and management of primary and secondary CNS malignancies from a standard lumbar puncture.
Belay Ascent™
Low-pass whole genome sequencing to detect chromosome arm-level losses and gains in CSF-derived nucleic acid to help inform the diagnosis and management of CNS malignancies. Can be ordered using the same patient specimen as Summit 2.0.
Belay Vantage™
Quantitative PCR evaluation of MGMT promoter methylation status in CSF for individuals with known or suspected CNS tumors. Can be ordered using the same patient specimen as Summit 2.0.
Belay Summit™ 2.0
Comprehensive genomic profiling of tumor-derived nucleic acid in CSF to help inform the diagnosis and management of primary and secondary CNS malignancies from a standard lumbar puncture.
Belay Ascent™
Low-pass whole genome sequencing to detect chromosome arm-level losses and gains in CSF-derived nucleic acid to help inform the diagnosis and management of CNS malignancies. Can be ordered using the same patient specimen as Summit 2.0.
Belay Vantage™
Quantitative PCR evaluation of MGMT promoter methylation status in CSF for individuals with known or suspected CNS tumors. Can be ordered using the same patient specimen as Summit 2.0.
